In contrast to CAD inhibitors, several DHODH inhibitors including brequinar (BRQ) and teriflunomide as well as its prodrug leflunomide have reached market approval as immunosuppressive agents in rheumatoid arthritis and multiple sclerosis. Here, DHODH is linked to multiple sclerosis.